Form 10-Q Pacira Pharmaceuticals, For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Pacira Pharmaceuticals (PCRX) PT Raised to $60 at RBC Capital
November 2, 2018 7:14 AM EDTRBC Capital analyst Randall Stanicky raised the price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $60.00 (from $55.00) while maintaining a Outperform rating.
... More


